Today: 22 January 2026
Subscribe
Browse Category

Pharmaceuticals News 22 July 2025 - 26 September 2025

Scholar Rock (SRRK) Just Hit a Regulatory Speed Bump—But the Long‑Term Muscle‑Building Story Still Has Legs

Scholar Rock (SRRK) Just Hit a Regulatory Speed Bump—But the Long‑Term Muscle‑Building Story Still Has Legs

Key facts (as of September 26, 2025) What happened this week (Sept. 23–26) Company snapshot & pipeline Scholar Rock is a late‑stage biotech developing apitegromab, a selective antibody that blocks latent myostatin activation to build/maintain skeletal muscle. Pipeline also includes SRK‑181 (anti‑latent TGF‑β1, oncology; Phase 1) and SRK‑439 (next‑gen anti‑latent myostatin; IND planned for 2H25).  Scholar Rock The SMA evidence base: apitegromab’s pivotal data The obesity tie‑in: preserving muscle…
26 September 2025
···
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Richmond’s New Pharma Giant: Overview of Lilly’s $5B Factory Eli Lilly’s forthcoming Richmond-area factory is set to be one of the largest and most advanced pharmaceutical manufacturing sites in the world. At a cost of $5 billion, Lilly will construct a high-tech production campus in Goochland County’s West Creek Business Park, a site that had been prepped for a previous…
16 September 2025
·
COVID Booster Shocker, Pharma Mega-Deals & Alzheimer’s Breakthroughs – Global Health Roundup (Aug 28–29, 2025)

COVID Booster Shocker, Pharma Mega-Deals & Alzheimer’s Breakthroughs – Global Health Roundup (Aug 28–29, 2025)

Drug Approvals & Clinical Trial Results Updated COVID Boosters Get Narrow Nod: The U.S. FDA approved new fall COVID-19 booster shots from Pfizer/BioNTech and Moderna on August 27 – but with strict eligibility limits. Only adults 65+ and younger people with certain medical conditions are cleared for the updated vaccines, and emergency use authorizations for routine use in healthy children…
29 August 2025
·
Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

Regulatory Approvals & Clinical Milestones Pharma & Biotech Industry Moves Startups & Innovation Highlights Medical Research & Innovation Public Health & Policy Developments Sources: Ionis HAE drug approval Pharmexec Biopharmadive; BioPharmaDive on Dawnzera pricing and positioning Biopharmadive Biopharmadive; AbbVie Rinvoq AA trial via FiercePharma Fiercepharma; Lancet Neurology SAPPHIRE trial results Neurologylive Neurologylive; Reuters – Kite/Gilead’s Interius acquisition Reuters and Interius…
23 August 2025
··
Global Biotech & Health Roundup: Breakthrough Drugs, Big Deals & Policy Shifts (Aug 21–22, 2025)

Global Biotech & Health Roundup: Breakthrough Drugs, Big Deals & Policy Shifts (Aug 21–22, 2025)

Pharmaceutical Industry News (Approvals, Trials & Deals) Biotech Startups & Funding Highlights Medical Research Breakthroughs & Publications Healthcare Policy & Public Health Developments Regulatory Updates from Agencies (FDA, EMA, etc.) Sources: Scientific press releases, company announcements, major news outlets (Reuters, AP, HealthDay, FierceBiotech, etc.), and health agency briefs were used to compile this report Reuters Reuters ts2.tech Interiusbio. Each item…
22 August 2025
···
Biotech Breakthroughs & Pharma Shakeups – Global Health Roundup (Aug 20–21, 2025)

Biotech Breakthroughs & Pharma Shakeups – Global Health Roundup (Aug 20–21, 2025)

Industry & Corporate Developments Mergers, Acquisitions & Partnerships Regulatory & Drug Approval Updates Public Health & Policy Research & Clinical Breakthroughs Sources: Reuters, Politico, HealthLeaders, BioPharma Dive, FierceBiotech, Pharmaceutical Executive, Technology Networks, McGill University Reuters Reuters Healthleadersmedia Reuters Fiercebiotech Reuters Reuters Technologynetworks Technologynetworks.…
21 August 2025
···
Biotech Breakthroughs, Pharma Shakeups & Health Alerts – Global News Roundup (Aug 19–20, 2025)

Biotech Breakthroughs, Pharma Shakeups & Health Alerts – Global News Roundup (Aug 19–20, 2025)

Major Corporate & Industry Announcements Clinical Trials & Drug Regulatory Updates Scientific & Medical Research Breakthroughs (Note: The above research highlights were reported in peer-reviewed journals and scientific news outlets around this time, underlining the broader scientific context during the news cycle.) Public Health & Policy Highlights Sources: Key information in this report is drawn from reputable industry and news…
20 August 2025
··
Biotech Breakthroughs, Pharma Power Moves & Health Shocks: News Roundup (Aug 18–19, 2025)

Biotech Breakthroughs, Pharma Power Moves & Health Shocks: News Roundup (Aug 18–19, 2025)

Biotech Sector – Big Deals, Funding, and FDA Drama Pharma & Drug Development – Approvals, Showdowns, and Safety Signals Medical & Clinical Updates – Guidelines and Safety Notices Public Health & Policy – Vaccine Rift, Medicare Cuts, and Wellness Initiatives Sources: Key news and expert quotes were gathered from Fierce Biotech Fiercebiotech Fiercebiotech, Fierce Pharma Fiercepharma Fiercepharma, Fierce Healthcare Fiercehealthcare…
19 August 2025
··
Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Wegovy (semaglutide) received FDA accelerated approval to treat metabolic dysfunction-associated steatohepatitis (MASH), becoming the first GLP-1 therapy cleared for MASH in a patient population estimated at about 5% of U.S. adults, based on part 1 of an ongoing trial showing liver health improvement. Tonix Pharmaceuticals’ Tonmya, or TNX-102 SL, was approved August 15 for fibromyalgia, the first new fibromyalgia therapy…
16 August 2025
···
Breakthrough Cures, FDA Shake-Ups & Pharma Mega‑Deals: Global Health News Roundup (Aug 9–10, 2025)

Breakthrough Cures, FDA Shake-Ups & Pharma Mega‑Deals: Global Health News Roundup (Aug 9–10, 2025)

Researchers in China unveiled a hydrogel-based “smart” wound dressing that speeds diabetic ulcer healing, with a single application achieving about 90% wound closure in 12 days by delivering microRNA-loaded vesicles that suppress the vessel-growth inhibitor TSP-1. A Swedish study published August 8 identified 87 DNA methylation sites in blood from 752 newly diagnosed diabetics followed for seven years, creating a…
10 August 2025
··
Revolutionary Medical Breakthroughs of July 2025: Life-Changing Drugs, Diagnostic Wonders & Public Health Milestones

Revolutionary Medical Breakthroughs of July 2025: Life-Changing Drugs, Diagnostic Wonders & Public Health Milestones

On July 2, 2025, the FDA granted accelerated approval to linvoseltamab (Lynozyfic), a BCMA-targeting bispecific antibody, for adults with heavily pretreated relapsed/refractory multiple myeloma, after trials showed a 70% response rate. Also on July 2, 2025, the FDA approved sunvozertinib (Zegfrovy) as the first targeted oral therapy for advanced NSCLC with EGFR exon 20 insertion mutations following chemotherapy. In July…
22 July 2025
···
1 … 43 44 45

Stock Market Today

  • Pro Medicus Leverages US Market to Strengthen Competitive Edge in Health-Tech
    January 22, 2026, 5:15 AM EST. Pro Medicus (ASX:PME), known for its advanced radiology imaging software and AI capabilities, is strengthening its position in the US hospital market through long-term contracts. The company competes effectively against larger legacy vendors, supporting its premium valuation despite recent share price declines. Investor focus centers on Pro Medicus' ability to sustain contract wins, margins, and cash flow ahead of its February 12, 2026 earnings report. Market sentiment remains fragile amid high valuation risks and expectations. Divergent fair value estimates, ranging from A$68.65 to over A$500, highlight varying investor perspectives on its growth prospects and US footprint. Pro Medicus' premium positioning in the specialized health-tech arena underpins its broader investment narrative.
Go toTop